EMA Withdrawn: Ivabradine JensonR (ivabradine hydrochloride) — JensonR+ Limited

View source ↗

Summary

The EMA has withdrawn Ivabradine JensonR (ivabradine hydrochloride) from the market under the MAH JensonR+ Limited, effective as of 11/11/2016, for therapeutic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Heart Failure

Drugs mentioned

• Ivabradine JensonR (ivabradine hydrochloride)

Snippet

Status: Withdrawn. Therapeutic area: Angina Pectoris;Heart Failure. MAH: JensonR+ Limited. Decision date: 11/11/2016